Rediscovery of metformin for the chronic disabling auto-inflammatory disease hidradenitis suppurativa - Metformin in HS

Erasmus MC, Department of Dermatology0 个研究点目标入组 62 人开始时间: 2021年3月16日最近更新: 2024年1月8日

适应症

试验速览

暂无简介。

•Age =18 years at baseline
•A diagnosis of HS for at least 1 year prior to baseline
•mild to moderately active disease defined by a HS Physician Global Assessment (HS-PGA)
•score of 2-3 and the Refined Hurley classification of mild to moderate at baseline
•Indication for systemic therapy; i.e. uncontrolled disease under conventional topical therapy.
•Able and willing to give written informed consent and to comply with the study requirements.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 62
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Pregnant and lactating women
•Concomitant diabetes mellitus
•Use of oral antibiotics within 14 days prior to baseline
•Use of immunosuppressing/modulating therapies within 28 days prior to baseline
•A known allergy to metformin or doxycycline or any of the ingredients metformin or doxycycline

发起方

Erasmus MC, Department of Dermatology